News

We are pleased to announce the recruitment of David Simarro González as joint PhD student co-financed by Université Claude Bernard Lyon 1 and A*STAR Infectious Diseases Labs - A*STAR IDL.After a 4-month internship at the La Fe Health Research Institute | IIS La Fe during his BSc degree in Biology, David obtained a MSc degree in Virology from the Universitat de València, including an 8-month internship at the Institute for Integrative Systems Biology i2sysbio working on new vaccine strategies...

Virnext was pleased to attend the BioFIT Event 2024. The event provided a great opportunity to present our expertise in emerging and re-emerging respiratory viruses, as well as our continuum of in vitro and in vivo preclinical models of infection. We had valuable discussions with many professionals about how we can support their research and development projects. During the event, we highlighted our key services: Production of high-quality, characterized viruses and viral vaccine antig...

This invention relates to a proprietary recombinant metapneumovirus strain we engineered as a versatile Live-Attenuated Viral vaccine platform that can express several antigens of interest.  METAVAC® patent was exclusively licensed worldwide to Vaxxel, a spin-off from the International Research Laboratory #RESPIVIR France – Canada. Based on the METAVAC® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus (RSV) and hum...

Emilie Laurent, Virnext research engineer, and Aurélien Traversier, Virnext assistant engineer, have been awarded the “Cristal collectif” by the CNRS for their major contributions to the Virocrib national infrastructure (https://www.virocrib.fr/) dedicated to the screening of antiviral molecules. The collective crystal award distinguishes teams of research support staff who have carried out projects whose technical mastery, collective dimension, applications, innovation and influence are...

Building on a structured and fruitful 15-year collaboration between Manuel Rosa-Calatrava’s team at Centre International de Recherche en Infectiologie, CIRI, Lyon and Guy Boivin's laboratory at Centre de Recherche du CHU de Québec - Université Laval, Québec, Didier Samuel, chairman and CEO of INSERM and Eugénie Brouillet, Vice-Rector in charge of Research, Creation and Innovation at Université Laval, have formalised RESPIVIR (www.respivir.io) as a joint laboratory. The aim of this 5-ye...

This invention relates to a proprietary recombinant metapneumovirus strain we engineered as a versatile Live-Attenuated Viral vaccine platform that can express several antigens of interest.  METAVAC® patent was exclusive licensed worldwide to Vaxxel, a spin-off of the International Research Laboratory RESPIVIR France – Canada and Virnext. Based on the METAVAC® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus RSV an...

Magnificent ceremony to confer the insignia of Doctor Honoris Causa of the Université Claude Bernard Lyon 1 on Guy Boivin, Full Professor of Paediatrics at the Faculté de Médecine de l'Université Laval and Microbiologist-Infectiologist at the Centre de Recherche en Infectiologie CHU de Québe – Université Laval. Under the honorary chairmanship of Olivier Dugrip, Recteur de la région académique Auvergne-Rhône-Alpes, Recteur de l'académie de Lyon, Chancelier des universités, Gabriel...

We are thrilled to present our latest newsletter, featuring the key accomplishments and scientific breakthroughs from our Technological Research Platform and its spin-offs during the 1st half of 2024. Read the English version here: https://lnkd.in/dKbmjeWKRead the French version here: https://lnkd.in/dJfYiF3A We sincerely appreciate your support and encourage you to share this update with your network....

Our study on the preclinical in vivo efficacy of Metavac®-RSV, an intranasal live-attenuated bivalent vaccine candidate against Respiratory Syncytial Virus and Human Metapneumovirus, has been published in Nature portfolio’s npj Vaccines. This study reports challenge studies performed on mice model showing that intranasal immunisation with Metavac®-RSV fully protects animals against infections with wild type HMPV and RSV, the main sources of bronchiolitis and viral pneumonia in children an...

Our spin-off Nexomis has developed a novel simulation method for generating connected differential expression signatures, based on a statistical framework that allows for adjustable levels of parametrization. This method directly addresses the issue of benchmarking data availability for connectivity-based drug repurposing approaches. This work was published in the journal Briefings in Bioinformatics (Oxford University press). It was elected article of the week by Drug Repurposing Research Collec...